Ario Khoshbin transitioning to Prollenium Board role; Walter Geiger Named as Acting CEO
Prollenium Medical Technologies (“Prollenium” or the “Company”) announced today that Ario Khoshbin is stepping down as Chief Executive Officer to focus on his role as a member of Prollenium’s Board of Directors. Ario remains a significant shareholder of Prollenium.
“Welcoming a CEO with new expertise and perspective will allow Prollenium to continue to achieve its potential as one of the world’s leading global developers and manufacturers of aesthetic products,” said Justin Bateman, Chair of Prollenium’s Board of Directors. “We appreciate and thank Ario for the significant contributions that he has made throughout his long and successful tenure as CEO. We will continue to work alongside the board and leadership team to scale Prollenium’s platform and convert its robust product pipeline into an expanding suite of products to serve both existing and new customers in North America and internationally.”
While the Board conducts a search for a successor, it has appointed Walter Geiger as acting Chief Executive Officer at Prollenium, effective immediately.
A seasoned executive, Walter most recently served as Chairman of the Board for Cellese Regenerative Therapeutics and as President of the Global Consumer Business Unit for Galderma. Prior to Galderma, he served in numerous senior leadership roles at Procter & Gamble, Johnson & Johnson, and Galderma, where he led small and large P&Ls across North America, Asia, and Europe.
“Prollenium’s success has been fueled by its commitment to product development, innovative research, and regulatory and manufacturing excellence,” said Walter Geiger, acting CEO at Prollenium. “I look forward to working with the Board and management team to ensure we continue to execute on its strategic priorities as we begin the next exciting chapter in Prollenium’s story.”
About Prollenium
Prollenium leads the way in facial aesthetics and rejuvenation technology, turning complex science into reliable, effective products. As the first FDA-approved dermal filler manufacturer in North America, Prollenium redefines standards with cutting-edge innovation, exceptional safety, and a portfolio tailored to patient needs.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250404365052/en/
Contacts
Andrew Merrill/Julia Sidi
Prollenium@prosek.com
